Patent 7300653 was granted and assigned to Regeneron Pharmaceuticals, Inc. on November, 2007 by the United States Patent and Trademark Office.
Methods of preventing, reducing, or treating corneal transplant rejection to improve transplant survival in a subject in need thereof comprising administering an agent capable of blocking or inhibiting vascular endothelial growth factor (VEGF) are provided. The methods are useful for inhibiting or preventing corneal transplant rejection in a human subject who is the recipient of a transplanted cornea.